首页|半夏泻心汤加减方对幽门螺杆菌相关性胃炎患者氧化应激指标及血清微小RNA-155可溶性白细胞介素-2受体的影响

半夏泻心汤加减方对幽门螺杆菌相关性胃炎患者氧化应激指标及血清微小RNA-155可溶性白细胞介素-2受体的影响

扫码查看
目的 探讨半夏泻心汤加减方对幽门螺杆菌(Hp)相关性胃炎患者氧化应激及血清微小RNA(miR)-155、可溶性白细胞介素-2受体(sIL-2R)的影响。方法 选取2022年1月至2022年12月在浙江省杭州市临平区中西医结合医院诊治的Hp相关性胃炎患者94例,按治疗方法分为2组,对照组47例和研究组47例,对照组给予四联疗法,研究组给予四联疗法+半夏泻心汤加减方治疗。比较2组治疗前后的中医证候积分、氧化应激指标、血清miR-155、sIL-2R,以及Hp转阴率、临床治疗疗效和不良反应发生情况。结果 相较于治疗前,2组治疗后中医证候积分降低(P<0。05),相较于对照组,研究组治疗后中医证候积分更低(P<0。05)。相较于治疗前,2组一氧化氮(NO)、丙二醛(MDA)治疗后降低(P<0。05),2组SOD治疗后升高(P<0。05),相较于对照组,研究组NO、MDA治疗后更低(P<0。05),研究组SOD治疗后更高(P<0。05)。相较于治疗前,2组miR-155、sIL-2R治疗后降低(P<0。05),相较于对照组,研究组miR-155、sIL-2R治疗后更低(P<0。05)。研究组Hp转阴率(87%)高于对照组(68%)(x2=4。967,P<0。05)。研究组治疗总有效率为91%高于对照组74%(x2=4。821,P<0。05)。对照组不良反应发生率9%,研究组6%,2组差异无统计学意义(x2=0。154,P>0。05)。结论 四联疗法+半夏泻心汤加减方治疗Hp相关性胃炎,可有效缓解症状,减轻应激反应,降低血清miR-155、sIL-2R水平,提高Hp转阴率和临床治疗疗效,且安全性高。
Effects of modified Banxia Xiexin Decoction on oxidative stress,serum miR-155,and sIL-2R in patients with Helicobacter pylori-related gastritis
Objective To explore the effects of Banxia Xiexin Decoction on oxidative stress,serum miR-155,and sIL-2R in patients with Helicobacter pylori(Hp)-related gastritis.Methods A total of 94 patients with Hp-related gastritis who were diagnosed and treated in Linping District Hospital of Integrated Traditional Chinese and Western Medicine from January 2022 to December 2022 were selected and divided into two groups by ran-dom number table method,the control group(47 cases)and the study group(47 cases).The control group was treated with quadruple therapy,while the study group was treated with quadruple therapy plus Banxia Xiexin De-coction.The TCM syndrome scores,oxidative stress indicators,serum miR-155,sIL-2R,Hp negative conversion rate,clinical treatment efficacy and adverse reactions were compared between the two groups before and after treatment.Results Compared with before treatment,the TCM syndrome scores in both groups decreased after treatment(P<0.05);and compared with the control group,the TCM syndrome scores in the study group were lower after treatment(P<0.05).Compared with before treatment,NO and MDA levels in both groups decreased after treatment(P<0.05),while SOD levels in both groups increased after treatment(P<0.05).Moreover,compared with the control group,NO and MDA levels in the study group were lower after treatment(P<0.05),and SOD levels in the study group were higher after treatment(P<0.05).Compared with before treatment,the levels of miR-155 and sIL-2R in both groups decreased after treatment(P<0.05).Furthermore,compared with the control group,the lev-els of miR-155 and sIL-2R in the study group were lower after treatment(P<0.05).The Hp negative conversion rate in the study group was 87%,significantly higher than the 68%in the control group after treatment(x2=4.967,P<0.05).The clinical treatment efficacy of the study group was better than that of the control group,and the total effective rate of treatment in the study group was 91%,significantly higher than the 74%in the control group(x2=4.821,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the control group(9%)and the study group(6%)(x2=0.154,P>0.05).Conclusion The combined treatment of quadru-ple therapy and Banxia Xiexin Decoction can effectively alleviate symptoms,reduce stress response,lower serum miR-155 and sIL-2R levels,improve Hp negative conversion rate and clinical treatment efficacy,with high safety

Ban Xia Xie Xin TangHelicobacter pyloriGastritisSoluble interleukin secondary re-ceptor

王静燕、方宏图、汪晓静、张思泉

展开 >

杭州市临平区中西医结合医院中医内科,浙江杭州 311199

杭州市余杭区第三人民医院中医内科,浙江杭州 311100

杭州市西溪医院内科,浙江杭州 310000

半夏泻心汤 幽门螺杆菌 胃炎 可溶性白细胞介素-2受体

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(18)